QSAR prediction of HIV-1 reverse transcriptase inhibitory activity of benzoxazinone derivatives

Internet Electronic Journal of Molecular Design

Volumn 11, Issue 1, 2012, Pages 363-374

  Ravichandran, Veerasamy ^a   Mourya, Vishnu Kant ^b   Agrawal, Ram Kishore ^a  

^a DR H S GOUR UNIVERSITY   (India)

^b GOVERNMENT COLLEGE OF PHARMACY   (India)

Author keywords

HIV 1 reverse transcriptase inhibitors; QSAR; Quantitative structure activity relationships

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 38149038721     PISSN: None     EISSN: 15386414     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. R. C. Gallo, S. Z. Salahuddin, M. Popovic, G. M. Shearer, M. Kaplan, B. F. Haynes, T. J. Palker, R. Redfield, J. Oleske and B. Safai, Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS, Science, 1984, 224, 500-503.
2. F. Barre-Sinoussi, J. C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum and L. Montagnier, Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), Science, 1983, 220, 868-871.
3. E. D. Clercq, Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections J. Med. Chem, 1995, 38, 2491-2517.
4. J. Milton, M. J. Slater, A. J. Bird, D. Spinks, G. Scott, C. E. Price, S. Downing, D. V. S. Green, S. Madar, R. Bethell and D. K. Stammers, Biaryl acids: Novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2, Bioorg. Med. Chem. Lett. 1998, 8, 2623-2628.
5. S. D. Young, S. F. Britcher, L. O. Tran, L. S. Payne, W. C. Lumma, T. A. Lyle, J. R. Huff, P. S. Anderson, D. B. Olsen and S. S. Carroll, L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase, Antimicrob. Agents Chemother. 1995, 39, 2602-2605.
6. M. Patel, R. J. McHugh, B. C. Cordova, R. M. Klabe, E. S. Viitnen, G. L. Trainor and J. D. Rodger, Synthesis and evaluation of benzoxazinones as HIV-1 reverse transcriptase inhibitors. Analogs of Efavirenz (SUSTIVA), Bioorg. Med. Chem. Lett.1999, 9, 3221-3224.
7. S. Balaji, C. Karthikeyan, N. S. Hari Narayana Moorthy and P. Trivedi, QSAR modeling of HIV-1 reverse transcriptase inhibition by benzoxazinones using a combination of P_VSA and pharmacophore feature descriptors, Bioorg. Med. Chem. Lett.1999, 14, 6089-6094.
8. P. R. Dutchowicz, M. Fernandez, J. Carballero, E. A. Castro and F. M. Fernandez, QSAR for non-nucleoside inhibitors of HIV-1 reverse transcriptase, Bioorg. Med. Chem. 2006, 14, 5876-5889.
9. J. T. Leonard and K. Roy, QSAR by LFER model of HIV protease inhibitor mannitol derivatives using FA-MLR, PCRA and PLS techniques, Bioorg. Med. Chem. 2006, 14, 1039-1046.
10. J. T. Leonard and K. Roy, Comparative QSAR modeling of CCR5 receptor binding affinity of substituted 1-(3,3-diphenylpropyl)-piperidinyl amides and ureas, Bioorg. Med. Chem. Lett. 2006, 16, 4467-4474.
11. G. Klebe, U. Abraham and T. Mietzner, Molecular similarity indices in a comparative analysis (COMSIA) of drug molecules to correlate and predict their biological activity, J. Med. Chem. 1994, 37, 4130-4146.
12. M. Bohm, J. Sturzebecher and G. Klebe, Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor, XaJ. Med. Chem. 1999, 42, 458-477.
13. J. K. Buolamwini and H. Assefa, CoMFA and CoMSIA 3D QSAR and docking studies on conformationally-restrained cinnamoyl HIV-1 integrase inhibitors: Exploration of a binding mode at the active site, J. Med. Chem. 2002, 45, 841-852.
14. A. C. Nair, P. Jayatilleke, X. Wang, S. Miertus and W. J. Welsh, Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor-and receptor based properties, J. Med. Chem. 2002, 45, 973-983.
15. P. Pungpo and S. Hannongbua, Three-dimensional quantitative structure-activity relationships study on HIV-1 reverse transcriptase inhibitors in the class of dipyridodiazepinone derivatives, using comparative molecular field analysis, J. Mol. Graphics & Modell. 2000, 18, 581-590.
16. P. R. N. Jayatilleke, A. C. Nair, R. Zauhar and W. J. Welsh, Computational studies on HIV-1 protease inhibitors: Influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models, J. Med. Chem. 2000, 43, 4446-4451.
17. M. L. Barreca, A. Carotti, A. Chimirri and A. M. Monforte, Comparative molecular field analysis (CoMFA) and docking studies of nonnucleoside HIV-1 RT inhibitors (NNIS), Bioorg. Med. Chem. 1999, 7, 2283-2292.
18. A. Hilgeroth, R. Fleischer, M. Wiese and F. W. Heinemann, Comparison of azacyclic urea A-98881 as HIV-1 protease inhibitor with cage dimeric N-benzyl 4-(4-methozyphenyl)-1, 4-dihydropyridine as representative of a novel class of HIV-1 protease inhibitors: a molecular modeling study, J. Computer-AidedMol. Design.1999,13, 233-242
19. A. K. Debnath, Three-dimensional quantitative structure-activity relationship study on cyclic urea derivatives as HIV-1 protease inhibitors: Application of comparative molecular field analysis, J. Med. Chem. 1999, 42, 249-259
20. V. Ravichandran and R. K. Agrawal, Predicting anti-HIV activity of PETT derivatives: CoMFA approach, Bioorg. Med. Chem. Lett. 2007, 17, 2197-2202
21. K. K. Sahu, V. Ravichandran, V.K. Mourya and R.K. Agrawal, QSAR analysis of caffeoyl naphthalene sulphonamide derivatives as HIV-1 Integrase inhibitors, Med. Chem. Res. 2007, 15, 418-430.
22. H. K. Jain and R. K. Agrawal, QSAR analysis of indomethacin derivatives as selective COX-2 inhibitors, Internet Electron. J. Mol. Des. 2006, 5, 224-236, http://www.biochempress.com.
23. H. K. Jain and R. K. Agrawal, Inhibitory mode of 2-acetoxyphenyl alkyl sulfides against COX-1 and COX-2: QSAR analyses, Bioorg. Med. Chem. Lett. 2006, 16, 5280-5284.
24. F. D. Frederik, H. Daeyaert, V. Maarten, M. R. D. Jonge, H. Jan, M. H. K. Lucien, P. J. Lewi and P. A. J. Janssen, Ligand-based computation of HIV-1 integrase inhibition strength within a series of β-ketoamide derivatives, Internet Electron. J. Mol. Des. 2004, 3, 528-543, http://www.biochempress.com.
25. M. Vracko and J. Gasteiger, A QSAR study on a set of 105 flavonoid derivatives using descriptors derived from 3D structures, Internet Electron. J. Mol. Des. 2002, 1, 527-544, http://www.biochempress.com.
26. A. V. Raichurkar and V. M. Kulkarni, 3D-QSAR of cyclooxygenase-2 inhibitors by genetic function approximation, Internet Electron. J. Mol. Des. 2003, 2, 242-261, http://www.biochempress.com.
27. S. M. Vadlamudi and V. M. Kulkarni, 3D-QSAR of protein tyrosine phosphatase 1B inhibitors by genetic function approximation, Internet Electron. J. Mol. Des. 2004, 3, 586-609, http://www.biochempress.com.
28. A. Hirashima, T. Eiraku, E. Kuwano, E. Taniguchi, and M. Eto, Three-dimensional pharmacophore hypotheses of octopamine receptor responsible for the inhibition of sex-pheromone production in Plodia interpunctella, Internet Electron. J. Mol. Des. 2002, 1, 37-51, http://www.biochempress.com.
29. A. Hirashima, E. Kuwano, and M. Eto, Three dimensional receptor surface model of octopaminergic agonists for the locust neuronal octopamine receptor, Internet Electron. J. Mol. Des. 2003, 2, 274-287, http://www.biochempress.com.
30. A. Hirashima, T. Eiraku, E. Kuwano, and M. Eto, Three-dimensional molecular field analyses of agonists for tyramine receptor which inhibit sex-pheromone production in Plodia interpunctella, Internet Electron. J. Mol. Des. 2003, 2, 511-526, http://www.biochempress.com.
31. M. Patel, R. J. McHugh, B. C. Cordova, R. M. Klabe, E. S. Viitnen, R. T. Bacheler, J. D. Rodger, Synthesis and evaluation of novel quinolinones as HIV-1 reverse transcriptase inhibitors, Bioorg Med. Chem. Lett. 2001, 11, 1943-1945.